Core Viewpoint - The brain-computer interface (BCI) industry is identified as a long-term investment opportunity in the healthcare sector, with significant strategic importance for the company in the medical device field [1] Summary by Relevant Sections Industry Outlook - The implementation opinions jointly issued by seven departments, including the Ministry of Industry and Information Technology, aim to establish an advanced technology, industry, and standard system for the BCI industry by 2027, and to cultivate 2 to 3 globally influential leading enterprises by 2030 [1] Company Strategy - The company has been researching and exploring the BCI direction since 2023 and strategically invested in Hangzhou Qingshi Yongjun in 2025, successfully entering the invasive BCI treatment field for severe treatment-resistant depression [1] - The recent investment in Haoshi Tianhui further enhances the company's detection and treatment layout for depression and anxiety disorders within the BCI field [1] Future Plans - The company plans to continue its strategic layout in the BCI field by participating deeply through its investment platform, using its own funds for equity participation or acquisitions to accelerate the product industrialization and commercialization processes of invested enterprises [1] - Additionally, the company intends to establish a BCI industry fund, leveraging the strengths and resources of professional investment institutions to expedite its industrial chain layout in the BCI and neuroscience fields [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Group 1 - The company announced a joint investment with Jiangsu Yingjue Private Equity Fund Management Co., Ltd. and Jiaxing Silin Venture Capital Partnership to establish Aipeng Zhilian Cloud Brain (Jiaxing) Equity Investment Partnership [1] - The company will act as a limited partner, contributing RMB 49.7 million, which represents a 49.7% stake in the investment fund [1] - The fund will primarily focus on equity investments in areas such as brain-computer interfaces, neuroscience, mental system diseases, and other healthcare sectors, with an investment period of 4 years and a total duration of 7 years [1]